Patents by Inventor Jiyun Chen

Jiyun Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240132449
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 25, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Jiyun CHEN, Son Minh PHAM
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240132522
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating PARP1 activity and may be used in the treatment of disorders in which PARP1 activity is implicated, such as cancer.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 25, 2024
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Aurelia CONTE, Jiyun CHEN, Son Minh PHAM
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 11826430
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: November 28, 2023
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
    Publication number: 20230339964
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: January 9, 2023
    Publication date: October 26, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanaka, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
    Publication number: 20230122310
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Application
    Filed: November 22, 2022
    Publication date: April 20, 2023
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Anup Barde, Anjan Kumar Nayak
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20230062022
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • Heterocyclic compounds as BET inhibitors
    Patent number: 11584756
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: February 21, 2023
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Chris P. Miller, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20230026856
    Abstract: The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and diseases using these inhibitors are also provided.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 26, 2023
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Son Minh PHAM, Sarvajit CHAKRAVARTY, Jiyun CHEN
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20230023009
    Abstract: The present disclosure relates to inhibitors of one or more isoforms of RAS, such as inhibitors of one or more of KRAS, HRAS and NRAS, or mutants thereof, such as G12D, G12V, G13D or G12C mutants thereof. Therapeutic methods of treating conditions and diseases using these inhibitors are also provided.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 26, 2023
    Inventors: Jayakanth KANKANALA, Jeremy D. PETTIGREW, Son Minh PHAM, Sarvajit CHAKRAVARTY, Jiyun CHEN
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220347187
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 3, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220281859
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Applicant: Nuvation Bio Inc.
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF
    Publication number: 20220220111
    Abstract: 1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: December 13, 2021
    Publication date: July 14, 2022
    Inventors: Son Minh Phan, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS
    Publication number: 20220213122
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: December 2, 2021
    Publication date: July 7, 2022
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • Diarylhydantoin compounds and methods of use thereof
    Patent number: 11292782
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: April 5, 2022
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
  • Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
    Patent number: 11192900
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors contanining substituted 2-pyridones and therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: December 7, 2021
    Assignee: Nuvation Bio Inc.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Jiyun Chen, Anjan Kumar Nayak, Anup Barde
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 11174252
    Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 16, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    Publication number: 20210292285
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 23, 2021
    Inventors: Son Minh PHAM, Jiyun CHEN, Amantullah ANSARI, Pradeep S. JADHAVAR, Varshavekumar S. PATIL, Farha KHAN, Sreekanth A. RAMACHANDRAN, Anil Kumar AGARWAL, Sarvajit CHAKRAVARTY
  • Pyrrole and pyrazole compounds and methods of use thereof
    Patent number: 11034669
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 15, 2021
    Assignee: Nuvation Bio Inc.
    Inventors: Sarvajit Chakravarty, Son Minh Pham, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anjan Kumar Nayak, Anup Barde, Brahmam Pujala
  • Heterocyclic compounds as adenosine antagonists
    Patent number: 11028058
    Abstract: Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: June 8, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Jiyun Chen, Amantullah Ansari, Pradeep S. Jadhavar, Varshavekumar S. Patil, Farha Khan, Sreekanth A. Ramachandran, Anil Kumar Agarwal, Sarvajit Chakravarty
  • HETEROCYCLIC COMPOUNDS AS BET INHIBITORS
    Publication number: 20210002293
    Abstract: Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 7, 2021
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Jiyun CHEN, Chris P. MILLER, Jeremy D. PETTIGREW, Anjan Kumar NAYAK, Anup BARDE